TY  - JOUR
AU  - Krieghoff-Henning, Eva
AU  - Michaeli, T.
AU  - Boch, Tobias
AU  - Kirchhof, J.
AU  - Haselmann, V.
AU  - Neumaier, M.
AU  - Hofmann, W-K
AU  - Betge, J.
AU  - Ebert, M.
AU  - Teufel, A.
AU  - Ast, V.
AU  - Sauer, C.
AU  - Cotarelo, C.
AU  - Lozynskyy, R.
AU  - Janning, M.
AU  - Marmé, F.
AU  - Sütterlin, M.
AU  - Streuer, A.
AU  - Siegel, F.
AU  - Brochhausen, C.
AU  - Collienne, M.
AU  - Nowak, D.
AU  - Loges, Sonja
TI  - Clinical benefit of additional whole-exome sequencing over panel sequencing in an all-comer real-world molecular tumor board.
JO  - ESMO open
VL  - 10
IS  - 12
SN  - 2059-7029
CY  - [London]
PB  - Elsevier
M1  - DKFZ-2025-02633
SP  - 105894
PY  - 2025
N1  - DKFZ-ZMBH Alliance / #EA:A420#EA:B340#LA:A420#
AB  - Panel sequencing, whole-exome sequencing (WES) and whole-genome sequencing (WGS) often uncover therapeutic targets for cancer patients. However, it is still largely unclear to what extent patients directly benefit from broader analyses over panel sequencing alone.We analyzed the molecular findings and recommendations issued by our molecular tumor board (MTB) in a cohort of patients who had received both a well-established diagnostic panel of medium size (up to 203 genes) and in-house WES, focusing on the number of recommendations that were issued on the basis of WES results only.Our cohort consisted of 38 patients with advanced cancers, of whom about two-thirds had common and one-third had rare cancers. They received a total of 45 (range 0-4) treatment recommendations overall, of which 29 had a clinical level of evidence (LoE) and/or entailed a feasible study enrollment and were thus considered highly actionable. Sixteen recommendations, of which seven were highly actionable, were issued only on the basis of WES results (five own, two previous WES). Three out of those seven recommendations and one additional recommendation based on a previous large panel were related to complex molecular biomarkers such as homologous recombination deficiency or high tumor mutational burden, with poly (ADP-ribose) polymerase inhibitors or checkpoint inhibitors as recommended treatment. As expected, a higher proportion of the WES-only recommendations (63
KW  - WES (Other)
KW  - biomarkers (Other)
KW  - molecular tumor board (Other)
KW  - panel sequencing (Other)
KW  - whole-exome sequencing (Other)
LB  - PUB:(DE-HGF)16
C6  - pmid:41297163
DO  - DOI:10.1016/j.esmoop.2025.105894
UR  - https://inrepo02.dkfz.de/record/306594
ER  -